Lars Franzén

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman et al. · The Lancet · 2019 · 840 citations

Surgical Oncology, Radiation Therapy, Medicine +8

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

Sten Nilsson, Lars Franzén, Christopher Parker et al. · The Lancet Oncology · 2007 · 491 citations

Bone-targeted Radium-223, Urology, Genitourinary Cancer +6

Parotid gland function during and following radiotherapy of malignancies in the head and neck

Lars Franzén, Ulrika Funegård, T. Ericson et al. · European Journal of Cancer · 1992 · 245 citations

Neuro-oncology, Radiation Therapy, Medicine +10

Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA)

Roger Henriksson, Jacek Capala, Annika Michanek et al. · Radiotherapy and Oncology · 2008 · 157 citations

Prolonged High-dose, Glioma, Radiation Therapy +10